TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells

نویسندگان

  • Sandra Pinet
  • Barbara Bessette
  • Nicolas Vedrenne
  • Aurélie Lacroix
  • Laurence Richard
  • Marie-Odile Jauberteau
  • Serge Battu
  • Fabrice Lalloué
چکیده

The neurotrophin receptors are known to promote growth and proliferation of glioblastoma cells. Their functions in spreading glioblastoma cell aggressiveness to the microenvironment through exosome release from glioblastoma cells are unknown. Considering previous reports demonstrating that YKL-40 expression is associated with undifferentiated glioblastoma cancer stem cells, we used YKL-40-silenced cells to modulate the U87-MG differentiated state and their biological aggressiveness. Herein, we demonstrated a relationship between neurotrophin-receptors and YKL-40 expression in undifferentiated cells. Differential functions of cells and derived-exosomes were evidenced according to neurotrophin receptor content and differentiated cell state by comparison with control pLKO cells. YKL-40 silencing of glioblastoma cells impairs proliferation, neurosphere formation, and their ability to induce endothelial cell (HBMEC) migration. The modulation of differentiated cell state in YKL-40-silenced cells induces a decrease of TrkB, sortilin and p75NTR cellular expressions, associated with a low-aggressiveness phenotype. Interestingly, TrkB expressed in exosomes derived from control cells was undetectable in exosomes from YKL-40 -silenced cells. The transfer of TrkB-containing exosomes in YKL-40-silenced cells contributed to restore cell proliferation and promote endothelial cell activation. Interestingly, in U87 MG xenografted mice, TrkB-depleted exosomes from YKL-40-silenced cells inhibited tumor growth in vivo. These data highlight that TrkB-containing exosomes play a key role in the control of glioblastoma progression and aggressiveness. Furthermore, TrkB expression was detected in exosomes isolated from plasma of glioblastoma patients, suggesting that this receptor may be considered as a new biomarker for glioblastoma diagnosis.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Assessment of the Diagnostic Value of GFAP, IGFBP-2, and YKL-40 in Patients with Glioblastoma

Background and Aims: An effective marker search in glioblastoma is precious in controlling and detecting the progression and monitoring of patients with glioblastoma. In this regard, the present study aimed to evaluate the diagnostic and prognostic role of glial fibrillary acidic protein (GFAP), insulin-like growth factor-binding protein -2 (IGFBP-2), and chitinase-3-like protein -1 (YKL-40) ti...

متن کامل

Exosome-loaded Paclitaxel: Preparation and toxicity evaluation on two glioblastoma cell lines

Objective(s): Exosomes are endogenous nanovesicles act as intercellular communication tools which have been considered to utilize as drug delivery systems. As transporting therapeutic molecules into brain has obstacles, preparing exosomes which have the potential to pass through its barriers is great challenge. Methods: Exosomes isolated from cell culture media of U87 glioblastoma ...

متن کامل

P154: Role of Exosomes as Novel Biomarkers in Diagnosis and Prognosis of Glioblastoma

Glioblastoma multiform(GBM) is the most prevalent primary brain tumor. Exosomes are extracellular vehicles for exchanging information between various cell types including cancer and normal cells. Exosomes are indicative of pathophysiological conditions of brain tumors that could be used in diagnosis and prognosis of GBM. In tumors, exosomes could carry various molecules like several miRNAs and ...

متن کامل

P112: Tumour Associated Macrophages and Vasculogenic Mimicry: A New Insight in Glioblastoma Treatment

Glioblastoma is one of the most common brain tumors in adults with poor prognosis, aggressiveness, and treatment resistance. Vasculogenic mimicry (VM) consists of generating vascular-like channels by tumor cells, independent of endothelial angiogenesis. Studies showed in glioblastoma, the proportion of VM to all vascular channels is associated with poor prognosis and higher invasiveness levels....

متن کامل

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial

YKL-40 is a glycoprotein with pro-angiogenic functions. We hypothesized that patients with newly diagnosed glioblastoma and low baseline plasma YKL-40 levels derive greater benefit from first-line bevacizumab. Plasma samples were collected from 563 patients in the randomized, phase 3 AVAglio trial who received bevacizumab or placebo plus radiotherapy/temozolomide. Raw plasma YKL-40 concentratio...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 7  شماره 

صفحات  -

تاریخ انتشار 2016